Choose your region

Don't see your region/country
listed? Visit our global website

Press Releases

Date Title and Summary Additional Formats
Oct 18, 2024
-- Phase 3 abstract selected for presentation in “Best Abstract” session -- BOSTON --(BUSINESS WIRE)--Oct. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective
Oct 10, 2024
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
BOSTON --(BUSINESS WIRE)--Oct. 10, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Sep 26, 2024
–   Phase 3 data on investigational vanza triple demonstrates non-inferiority to TRIKAFTA ® in ppFEV 1 and further improvement of CFTR function as measured by sweat chloride – –   Real-world evidence and clinical studies of TRIKAFTA ® continue to show sustained long-term benefits including
Aug 22, 2024
Vertex to Participate in Upcoming September Investor Conferences
BOSTON --(BUSINESS WIRE)--Aug. 22, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani , Chief Executive Officer and President, and Charles Wagner , Executive Vice President and Chief
Aug 07, 2024
- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today - - CASGEVY is one of the first medicines funded by NHS England’s Innovative Medicines Fund - LONDON --(BUSINESS WIRE)--Aug. 7, 2024-- Vertex Pharmaceuticals (Nasdaq: VRTX)
Aug 01, 2024
Vertex Reports Second Quarter 2024 Financial Results
— Product revenue of $2.65 billion , a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025 ; additionally, MAA
Jul 30, 2024
– FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 – – Suzetrigine, an investigational non-opioid pain signal inhibitor, has the potential to treat millions of patients who suffer from moderate-to-severe acute pain each year –
Jul 02, 2024
- Vanza triple granted priority review with Prescription Drug User Fee Act (PDUFA) target action date of January 2, 2025 – - EU Marketing Authorization Application (MAA) submission also validated by European Medicines Agency (EMA) BOSTON --(BUSINESS WIRE)--Jul.
Jul 01, 2024
Vertex to Announce Second Quarter 2024 Financial Results on August 1
BOSTON --(BUSINESS WIRE)--Jul. 1, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
Jun 21, 2024
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients
Jun 14, 2024
- Results from CLIMB-111, -121 and -131 accepted for oral presentation - - Data from these trials, with the longest follow-up of more than five years, demonstrate transformative, consistent and durable benefit of CASGEVY™ - - Safety profile consistent with busulfan conditioning and   autologous
Jun 07, 2024
- Results from a randomized, placebo-controlled study of TRIKAFTA ® in people with cystic fibrosis with rare, non- F508del CFTR mutations showed statistically significant and clinically meaningful improvements in the primary and all secondary endpoints - - Interim results of largest real-world
May 22, 2024
Vertex to Participate in Upcoming June Investor Conferences
BOSTON --(BUSINESS WIRE)--May 22, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the William Blair 44 th Annual Growth Stock
May 15, 2024
Jennifer Schneider Elected to Vertex Board of Directors
BOSTON --(BUSINESS WIRE)--May 15, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider , M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry
May 06, 2024
Vertex Reports First Quarter 2024 Financial Results
— Product revenue of $2.69 billion , a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — — Initiated rolling NDA
Apr 26, 2024
-   KALYDECO   ® is the first and only medicine approved in the EU in this age group to treat the underlying cause of cystic fibrosis for specific mutations in the CFTR gene - LONDON --(BUSINESS WIRE)--Apr. 26, 2024-- Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European
Apr 23, 2024
Vertex obtains an exclusive license to TreeFrog's C-Stem TM   manufacturing technology in type 1 diabetes  TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells  BOSTON and BORDEAUX, France , April 23, 2024 /PRNewswire/ -- Vertex
Apr 18, 2024
– Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter – – Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy (DPN); Phase 3 program to
Apr 10, 2024
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine’s lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept
Apr 09, 2024
Vertex to Announce First Quarter 2024 Financial Results on May 6
BOSTON --(BUSINESS WIRE)--Apr. 9, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .